RESUMO
Based on our experience in treating one patients with non-small cell lung cancer complicated with hyperthyroidism,the following considerations in immunotherapy and pharmaceutical care are proposed:role of iodine contrast and contrast agent selection in patients with hyperthyroidism;selection of hemostatic agents and assessment of thrombosis risk in patients with hemoptysis caused by tumor invasion of bronchus;influence of glucocorticoid use on the treatment with programmed cell death-1(PD-1)inhibitor and the role of PD-1 inhibitors in patients with a history of hyperthyroidism;education methods for patients refuse to receive opioids.The participation of clinical pharmacists in the Multiple Disciplinary Team and the multi-dimensional pharmaceutical monitoring for patients can improve the safety and rationality of medications.
RESUMO
OBJECTIVE: To evaluate the relative bioavailibility and bioequivalence of paroxetine hydrochloride film-coated tablets. METHODS: In a randomized crossover study, 24 healthy Chinese male subjects received a single oral dose (20 mg) of either test or reference paroxetine hydrochloride tablets after an overnight fast. The plasma concentrations of paroxetine were determined by a validated LC-MS/MS method. The pharmacokinetic parameters, the relative bioavailability and bioequivalence of two formulations were evaluated by DAS 2.0 software. RESULTS: After a single oral dose of 20 mg test or reference paroxetine tablets, the pharmacokinetic parameters of paroxetine were as follows: ρmax(5.102 ± 2.955) and (5.396 ± 2.852) μg · L-1; tmax (5.22 ± 1.83) and (5.35 ± 0.78) h; t1/2(11.76 ± 2.91) and (11.98 ± 3.57) h; AUC0~96h(118.1 ± 90.2) and (118.9 ± 86.0) μg · h · L-1; AUC0-∞ (120.2 ± 91.0) and (121.5 ± 87.6) μg · h · L-1, respectively. CONCLUSION: The relative bioavailability of the test paroxetine hydrochloride film-coated tablets is (100.6 ± 22.0)%. The two preparations are bioequivalent. Copyright 2012 by the Chinese Pharmaceutical Association.